By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


SEARCH JOBS








Company News
Boehringer Ingelheim And Eli Lilly (LLY) Release: Jardiance (Empagliflozin) Significantly Reduced The Risk Of Progressive Kidney Disease In Adults With Type 2 Diabetes With Established Cardiovascular Disease 6/14/2016 10:36:23 AM
Boehringer Ingelheim And Eli Lilly (LLY) Release: New Study Results Show Trajenta (Linagliptin) Reduces Blood Sugar In Adults With Type 2 Diabetes At Risk For Kidney Impairment 6/13/2016 10:53:16 AM
Boehringer Ingelheim And HealthPrize Partner To Launch New Support Program For People Treating COPD With SPIRIVA RESPIMAT (Tiotropium Bromide) Inhalation Spray 6/8/2016 10:32:54 AM
Boehringer IngelheimAnd Harvard Scientists Establish A Research Alliance To Find Novel Treatments For Severe Fibrotic Diseases 6/7/2016 8:34:39 AM
ASCO2016: New Data On Olmutinib (BI 1482694) Presented At ASCO 2016 Underscores Clinical Potential Of Boehringer Ingelheim’s Next Generation Lung Cancer Compound 6/6/2016 1:20:02 PM
Boehringer Ingelheim Launches Ambitious ELUXA Trial Programme To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016 10:39:25 AM
Boehringer Ingelheim Launches Ambitious ELUXA Trial Program To Broadly Investigate Promising Lung Cancer Compound Olmutinib 6/2/2016 8:57:14 AM
Boehringer Ingelheim, Inventiva Ink EUR170 Million Idiopathic Pulmonary Fibrosis Deal 5/31/2016 6:35:59 AM
Boehringer Ingelheim Release: 3 Out Of 4 People With Symptomatic Asthma Report Reduced Productivity At Work 5/26/2016 10:53:08 AM
Boehringer Ingelheim Release: IL-23 Inhibitor Risankizumab Induces Remission In Phase II Study In Patients With Moderate-To-Severe Crohn’s Disease 5/24/2016 9:59:16 AM
12345678910...
//-->